北京大学 | ENGLISH
讲座信息
Defining the best targets for effective cancer therapy
发布时间:2012-10-29      点击量:879
主讲人:Gerard Evan
讲座地点:生命学院101报告厅
讲座日期:2012-10-30
联系人:张研,电话:62754880
 
学术报告
题目:Defining the best targets for effective cancer therapy
报告人:Prof. Gerard Evan
Head of Department of Biochemistry, University of Cambridge
时间:2012年10月30日(周二),上午10:30-11:30 AM
地点:生命学院101报告厅

Cancers are difficult pathologies to cure because tumor cells adapt and evolve in response to target inhibition. Hence, the major issue confounding efficacy of cancer drugs is the extent of functional redundancy (either innate, adaptive or acquired through mutation and selection) of the target. For this reason, we have developed novel, switchable genetic mouse models that allow us to regulate the activities of (currently) untargetable intracellular effector nodes that are functionally non-redundant: Ras, Myc, and E2F. In this way, we model, in pre-clinical mouse cancer models in vivo, the therapeutic index of inhibiting these specific effectors in various tumor models. The Myc oncoprotein is functionally deregulated in almost all human cancers, even though the gene is frequently not, of itself, mutated. Using switchable genetic mouse models in which endogenous Myc function can be systemically and reversibly inhibited in normal and tumour tissues in vivo, we demonstrate that inhibiting Myc has a remarkably efficacious and durable therapeutic impact on multiple cancer types while eliciting only mild, reversible and non-cytotoxic side effects in normal tissues. Moreover, in keeping with the non-redundant nature of Myc in proliferation, we never see the emergence of resistant clones since the requirement for Myc cannot be circumvented. Using a different switchable technology, we have also investigated the therapeutic potential of inhibiting mitogenic E2F activity. The p53 tumor suppressor is functionally inactivated in many tumor types, suggesting that p53 restoration might be therapeutically effective. Using a mouse in which endogenous p53 can be systemically and reversibly switched between inactive and active states in vivo, similarly, we use switchable genetics to model the therapeutic efficacy of restoring p53 in various cancer types and at various stages of their evolution. Our studies indicate unexpected ways in which p53`s chequered evolutionary legacy has compromised its efficacy as a tumour suppressor and indicate inherent limits in the efficacy of p53-restoration as a cancer therapy.

欢迎各位老师和同学积极参加!
[友情链接]
北大生科微信公众号 生声不息微信公众号
联系我们 | 地理位置
北京大学生命科学学院 版权所有 地址:北京市海淀区颐和园路5号金光生命科学大楼